Changes in signal transduction and disease Knowledge-Based Study

Study notes

1. Overview of Cellular Communication

   Cellular communication relies on precisely coordinated signal transduction pathways. A typical pathway consists of three core stages:

   • Reception: A signaling molecule (ligand) binds specifically to a target cell receptor, such as a G-protein-coupled receptor (GPCR) or a receptor tyrosine kinase (RTK).
   • Transduction: The binding event induces a conformational change in the receptor, initiating a cascade of molecular interactions. This relay often involves phosphorylation cascades catalyzed by protein kinases and second messengers such as cyclic AMP (cAMP) or calcium ions (Ca2+).
   • Cellular Response: The transduced signal triggers a specific cellular outcome, such as gene transcription, enzyme activation, metabolic changes, or cell division.

   Under normal physiological conditions, these pathways possess tightly controlled on and off switches to prevent prolonged or inappropriate signaling.

   Mechanisms of Pathway Dysregulation

   Signal transduction pathways can be compromised by genetic mutations, environmental toxins, or pathogenic organisms. Disruptions usually alter the activity or abundance of key pathway components:

   • Constitutive Activation: A gain-of-function mutation can lock a receptor, relay protein, or enzyme in a permanently active state. For example, a mutation in the RAS gene can prevent the Ras G-protein from hydrolyzing GTP to GDP, leading to continuous downstream signaling for cell proliferation, even in the absence of an upstream growth factor.
   • Loss of Function: A mutation may prevent receptor synthesis, block ligand binding, or produce non-functional enzymes, thereby eliminating normal cellular responses. In many forms of Type 2 diabetes, for instance, insulin receptors or downstream signaling molecules become resistant or unresponsive to insulin, disrupting glucose uptake.
   • Impaired Termination: Pathways depend on enzymes such as protein phosphatases and phosphodiesterases to turn off signals. Deficiencies in these regulatory enzymes allow signals to persist abnormally long.

   Exogenous Interference in Signal Cascades

   Many infectious diseases arise because bacterial toxins directly manipulate host signal transduction machinery:

   • Cholera Toxin: Produced by Vibrio cholerae, cholera toxin chemically modifies the alpha subunit of a stimulatory G-protein (Gs) in intestinal epithelial cells. This modification prevents Gs from hydrolyzing GTP to GDP, locking it in an active state. As a result, adenylyl cyclase remains persistently active, causing an excessive accumulation of cAMP. Elevated cAMP opens chloride channels, leading to a massive efflux of chloride ions and water into the intestinal lumen, causing severe dehydration.
   • Pertussis Toxin: Produced by Bordetella pertussis, this toxin inactivates inhibitory G-proteins (Gi), preventing them from downregulating adenylyl cyclase. This similarly leads to abnormally high levels of cAMP and disrupted cellular regulation.
   • Anthrax Toxin: The lethal factor component of anthrax toxin acts as a protease that cleaves mitogen-activated protein kinase kinases (MAPKKs), completely blocking critical MAPK signaling pathways needed for immune cell survival.

   Pharmacological Interventions

   Understanding the molecular basis of aberrant signaling has enabled the development of targeted therapies that restore balance or inhibit overactive pathways:

   • Kinase Inhibitors: Small molecules can bind to the ATP-binding pockets of hyperactive kinases. For instance, imatinib (Gleevec) specifically inhibits the BCR-ABL fusion protein kinase, an abnormally active enzyme in chronic myelogenous leukemia (CML), blocking malignant cell proliferation.
   • Monoclonal Antibodies: Designed antibodies can bind to extracellular receptor domains to prevent ligand binding or receptor dimerization. For example, trastuzumab (Herceptin) targets the HER2 receptor in specific types of breast cancer, preventing aberrant growth signaling.
   • Receptor Antagonists and Agonists: Antagonists block overactive receptors, such as beta-blockers damping excessive adrenergic signaling in cardiovascular diseases, while agonists stimulate pathways that are deficient.